Minjon Lenneke, Brozina Ivona, Egberts Toine C G, Heerdink Eibert R, van den Ban Els
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands.
Front Psychiatry. 2021 Feb 25;12:640377. doi: 10.3389/fpsyt.2021.640377. eCollection 2021.
To assess the frequency of monitoring of adverse drug reaction (ADR) related parameters in children and adolescents treated with antipsychotic drugs in psychiatric outpatient clinics and the considerations when monitoring was not performed. This retrospective follow-up study included 100 randomly selected outpatients aged ≤18 years who had a first prescription of an antipsychotic drug recorded in the electronic medical records of psychiatric outpatient clinics between 2014 and 2017. They were followed for up to 3 years. This study assessed the frequency of monitoring for physical parameters (weight, height, body mass index, waist circumference, pulse, blood pressure, and an electrocardiogram) and laboratory parameters (glucose, lipids, and prolactin) before the first prescription of an antipsychotic drug as well as during its use. Monitoring frequencies were stratified by the patient characteristics (sex, age, cardiovascular risk factors, and use of other psychotropic drugs), and by location of antipsychotic drug initiation (psychiatric outpatient clinic or elsewhere). Additionally, this study assessed the considerations mentioned in the medical records for not monitoring ADR-related parameters. Overall, physical parameters were monitored more frequently (weight: 85.9% during the first half-year) than laboratory parameters (glucose and cholesterol: both 23.5%). There were no significant differences in monitoring at least one physical as well as in monitoring at least one laboratory parameter during the baseline period and during the total follow-up of antipsychotic drug treatment between the patient characteristics. In total, 3% of the children and adolescents were never monitored for any physical parameter, and 54% were never monitored for any laboratory parameter. For a minority of the children (14.8%) who were never monitored for laboratory parameters, considerations were recorded in their medical records, including refusal by the child or parents and monitoring performed by the general practitioner or elsewhere. Monitoring frequencies of ADR-related parameters in children and adolescents treated with antipsychotic drugs in psychiatric outpatient clinics varied and especially monitoring of laboratory parameters was infrequent. Considerations why monitoring was not performed were rarely recorded. The optimal method of monitoring and documentation thereof should become clear to optimize the benefit-risk balance of antipsychotic drug treatment for each child.
评估精神科门诊中接受抗精神病药物治疗的儿童和青少年的药物不良反应(ADR)相关参数的监测频率,以及未进行监测时的考虑因素。这项回顾性随访研究纳入了100名随机选择的年龄≤18岁的门诊患者,他们在2014年至2017年期间首次开具抗精神病药物的处方记录在精神科门诊的电子病历中。对他们进行了长达3年的随访。本研究评估了在首次开具抗精神病药物处方之前以及用药期间身体参数(体重、身高、体重指数、腰围、脉搏、血压和心电图)和实验室参数(血糖、血脂和催乳素)的监测频率。监测频率按患者特征(性别、年龄、心血管危险因素和其他精神药物的使用情况)以及抗精神病药物起始地点(精神科门诊或其他地方)进行分层。此外,本研究评估了病历中提及的未监测ADR相关参数的考虑因素。总体而言,身体参数的监测频率更高(上半年体重监测频率为85.9%),高于实验室参数(血糖和胆固醇监测频率均为23.5%)。在基线期以及抗精神病药物治疗的整个随访期间,根据患者特征,至少监测一项身体参数以及至少监测一项实验室参数的情况没有显著差异。总的来说,3%的儿童和青少年从未接受过任何身体参数的监测,54%的儿童和青少年从未接受过任何实验室参数的监测。对于少数从未接受过实验室参数监测的儿童(14.8%),病历中记录了相关考虑因素,包括儿童或家长拒绝以及由全科医生或其他地方进行的监测。精神科门诊中接受抗精神病药物治疗的儿童和青少年的ADR相关参数监测频率各不相同,尤其是实验室参数的监测很少。很少记录未进行监测的原因。应明确监测和记录的最佳方法,以优化每个儿童抗精神病药物治疗的获益-风险平衡。